Berberine, an isoquinoline alkaloid, has been recognized for its multiple pharmacological properties, including antimicrobial, anti-inflammatory, and antidiabetic effects. The current study shines a spotlight on berberine’s antifungal abilities, specifically its action against Fonsecaea monophora. The research highlights how berberine interferes with the growth and replication of this pathogen, which poses a significant threat in healthcare environments, where its prevalence has been linked to increased morbidity and mortality.

The study employed rigorous in vitro methodologies to elucidate berberine’s antifungal mechanisms. By subjecting Fonsecaea monophora cultures to various concentrations of berberine, researchers observed a significant reduction in fungal viability. The minimum inhibitory concentration (MIC) was meticulously determined, showcasing berberine’s potential as a viable alternative to conventional antifungal agents, which are often limited due to resistance issues. This aspect of the research is critical, as the rise of antifungal resistance remains a significant concern for healthcare systems worldwide.

Further investigation into the mechanisms underpinning berberine’s antifungal action unveiled that it disrupts cellular integrity and hampers crucial metabolic pathways within Fonsecaea monophora. Electron microscopy studies revealed structural anomalies in the fungal cell walls when exposed to berberine, indicating compromised cell wall integrity and potential disruption of cell membrane function. These findings provide a detailed understanding of how berberine acts at the cellular level, offering insights that may pave the way for new antifungal therapies.

In vivo experiments complemented the in vitro findings, affirming the efficacy of berberine in a living organism model. The researchers utilized animal models that were deliberately infected with Fonsecaea monophora to ascertain berberine’s therapeutic potential. Remarkably, administration of berberine resulted in significant survival benefits and reduced fungal loads, underscoring its promise as a therapeutic agent. This dual approach—combining in vitro and in vivo results—strengthens the validity of the findings and suggests a real potential for berberine in clinical applications.

The research team, under the leadership of L. He, along with co-authors Y. Zhu and X. Mei, advocates for the integration of berberine into treatment protocols, particularly given its relatively low toxicity profile and accessibility as a natural compound. The fact that berberine has already been widely used in traditional medicine for various ailments bolsters the argument for its integration into modern medical practices. Their call to action emphasizes the need for further clinical trials to fully establish berberine’s antifungal profile and confirm its safety and efficacy in human subjects.

The study does not merely end with highlighting the potential of berberine; it also alludes to the necessity for new laboratory-based approaches to tackle rising antifungal resistance. The rise of drug-resistant strains of fungi like Fonsecaea monophora underlines an urgent need for innovative strategies in antifungal therapy. Berberine offers a multifaceted approach that not only tackles existing infections but may also play a role in preliminary preventative measures against fungal colonization, especially in vulnerable populations.

This groundbreaking research also opens the floor for discussions about the broader implications of employing natural products in the fight against infectious diseases. The trend of exploring traditional herbal medicines for antimicrobial properties is gaining momentum, with various studies documenting the efficacy of other compounds similarly derived from plants. This research by He et al. adds to a growing body of evidence supporting the scientific investigation of herbal medicine principles and their utility in modern therapeutics.

Furthermore, these findings could also inspire researchers to delve deeper into the synergy between berberine and other antifungal agents, exploring potential combination therapies that may lead to more effective treatments. The researchers hint at the need for exploratory studies examining the co-administration of berberine with existing antifungal drugs to enhance therapeutic outcomes. This multifaceted approach may be crucial in devising strategies that mitigate resistance development.

In summary, the study conducted by L. He and his colleagues represents a significant advancement towards understanding and potentially mitigating the threat posed by Fonsecaea monophora. The documented inhibitory effects of berberine not only underscore its potential as an effective antifungal agent but also highlight the importance of exploring natural products as viable treatment options in an era where drug resistance is rampant. Their findings warrant further exploration and clinical validation, paving the way for new treatment paradigms in infectious disease management.

In light of the results from this study, it becomes increasingly clear that a thorough reevaluation of existing antifungal therapies is necessary. By incorporating naturally derived compounds like berberine into clinical practice, the healthcare community may find themselves better equipped to tackle the persistent and evolving challenges posed by fungal infections. This research sparks hope and optimism for new frontiers in the battle against infectious diseases, reminding us that nature often holds the key to solutions for modern medical dilemmas.

As we await further validation in clinical trials, the prudent message remains: exploring alternatives rooted in nature may very well lead us to innovative solutions in an increasingly complex medical landscape. The findings of this study serve as a stepping stone, urging researchers and clinicians alike to pursue the integration of natural compounds like berberine into contemporary medicine, bolstering our defenses against the ever-evolving threats of fungal pathogens.

Subject of Research: Inhibitory effects of berberine on Fonsecaea monophora

Article Title: Inhibitory effects of berberine on Fonsecaea monophora in vitro and in vivo

Article References:

He, L., Zhu, Y., Mei, X. et al. Inhibitory effects of berberine on Fonsecaea monophora in vitro and in vivo.
BMC Complement Med Ther 25, 387 (2025). https://doi.org/10.1186/s12906-025-05121-4

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05121-4

Keywords: berberine, Fonsecaea monophora, antifungal, in vitro, in vivo, drug resistance, natural compounds

In the field of oncology, where the stakes are high and patient vulnerability is at its peak, the adherence to standard precautions by healthcare professionals is of paramount importance. An illuminating study by Tarakcioglu Celik and Ozdemir explores this vital aspect, shedding light on oncology nurses’ compliance with these precautions through a multi-method approach. The researchers meticulously investigated various factors influencing adherence, revealing insights that are critical not only for patient safety but also for the well-being of healthcare workers themselves.

Standard precautions are infection control measures that should be employed by all healthcare providers to prevent the transmission of pathogens. They encompass a range of practices, including hand hygiene, use of personal protective equipment (PPE), and safe disposal of medical waste. Despite their proven efficacy, studies have consistently highlighted gaps in compliance among healthcare professionals, specifically oncology nurses who frequently interact with immunocompromised patients. This raises a pressing concern: What are the barriers these professionals face, and how can we enhance compliance rates?

The study employs a mixed-methods approach, combining quantitative surveys and qualitative interviews with oncology nurses. This innovative methodology allows the researchers to capture a comprehensive view of compliance levels and the factors that underlie them. The results of the survey, which included responses from over 200 oncology nurses, provide a robust statistical foundation for understanding compliance rates across different healthcare settings. Surprisingly, while a significant portion of participants reported understanding the importance of standard precautions, only a minority adhered consistently to these practices during daily operations.

One of the key findings of the research is the role of education and training in promoting compliance with standard precautions. Many nurses expressed that while initial training had provided them with the necessary knowledge about infection control, ongoing education was lacking. The healthcare environment is constantly evolving, and so too are the strategies for effective infection control. Continuous professional development is critical; with regular updates and training sessions, nurses can stay informed about the latest best practices and guidelines, thus enhancing their compliance cultures.

Moreover, the study reveals organizational factors that significantly impact compliance. Nurses reported that institutional policies sometimes hindered their ability to implement standard precautions effectively. For instance, inadequate availability of PPE or unclear protocols can create confusion and, ultimately, non-compliance. The research underscores the importance of supportive infrastructure within healthcare organizations that not only provides resources but also fosters an environment where compliance is the norm rather than the exception.

Beyond organizational influences, individual factors such as stress and workload also play a crucial role in adherence to standard precautions. Oncology nursing is a demanding field, often characterized by high patient ratios and emotional strain. Many nurses expressed that the increasing pressure to deliver patient care could distract them from strict adherence to infection control measures. This finding prompts a broader discussion about the importance of mental well-being and manageable workloads in healthcare settings.

Furthermore, the qualitative interviews reveal that a culture of safety within healthcare teams significantly enhances compliance levels. When nurses feel supported by their colleagues and supervisors, they are more likely to adhere to standard precautions. An environment that encourages open communication and team collaboration creates a dynamic where compliance becomes a collective responsibility. The researchers emphasize the importance of fostering such cultures to improve not only patient outcomes but also staff morale.

In exploring the nurse-patient dynamic, the study highlights the importance of effective communication about infection control measures. Patients, particularly those undergoing oncology treatment, are often anxious and concerned about their safety. When nurses take the time to explain the rationale behind standard precautions, it not only reinforces compliance but also builds trust and rapport with patients. This two-way communication serves to empower patients, reassuring them that their safety is the priority of the healthcare team.

Ultimately, the researchers conclude that a multi-faceted approach is necessary to improve compliance among oncology nurses. This includes enhanced training initiatives, supportive organizational policies, and a focus on building a collaborative healthcare culture. By addressing both systemic and individual barriers, healthcare institutions can foster an environment where standard precautions are not just policies to follow, but integral components of daily nursing practice.

As healthcare continues to evolve, the insights gleaned from this study are particularly relevant in light of ongoing challenges posed by infectious diseases. The importance of rigorous adherence to infection control measures cannot be overstated, especially in oncology departments where the patient population is inherently more vulnerable. These findings serve as a call to action for healthcare leaders to prioritize compliance strategies, ensuring that nurses are both equipped and empowered to perform their duties safely.

In conclusion, the study conducted by Tarakcioglu Celik and Ozdemir is a significant contribution to our understanding of infection control practices in oncology nursing. It serves not only to shed light on current compliance levels but also to propose actionable strategies for improvement. As we advance in the quest for excellence in patient care, insights like these help pave the way for stronger, more resilient healthcare systems.

Subject of Research: Oncology nurses’ compliance with standard precautions.

Article Title: Oncology nurses’ compliance with standard precautions: a multi-method study.

Article References:

Tarakcioglu Celik, G.H., Ozdemir, E. Oncology nurses’ compliance with standard precautions: a multi-method study. BMC Nurs 24, 1125 (2025). https://doi.org/10.1186/s12912-025-03788-1

Image Credits: AI Generated

DOI: 10.1186/s12912-025-03788-1

Keywords: oncology, nurses, standard precautions, infection control, compliance, healthcare, barriers, safety culture.

Pseudomonas aeruginosa is widely recognized as a major player in chronic infections, especially in immunocompromised patients, such as those with cystic fibrosis or complex surgical wounds. The ability of this bacterium to produce pyocyanin, a blue-green pigment, serves not only as a marker for its presence but is also directly linked to its pathogenicity. Recent advancements in microbiological research underscore the need for reliable detection methods, as early identification of P. aeruginosa can drastically alter the course of treatment and improve prognoses.

The current detection methods for pyocyanin often rely on expensive and sophisticated instrumentation or lengthy procedures, making widespread implementation in clinical settings impractical. In this study, the team turned to Dickeya zeae WH1, a bacterium known for its unique sensing capabilities, as a potential solution. By leveraging the natural responsive mechanisms of D. zeae, the researchers aimed to engineer a more accessible and efficient detection platform.

The foundation of the biosensor lies in the biochemical interactions between pyocyanin and specific receptor proteins expressed by Dickeya zeae WH1. These proteins have evolved to detect and respond to various environmental cues, including the presence of other microbial metabolites. By fusing these receptors with a transducer mechanism, the researchers were able to convert the chemical signal of pyocyanin into an easily measurable response, enabling real-time monitoring of bacterial activity.

The study presents a meticulous methodology that outlines the procedures for integrating D. zeae WH1 into a lab-based setting. The researchers detail the cultivation of the bacterium, the extraction of the receptor proteins, and the optimization of the sensing system to enhance its sensitivity and specificity. Remarkably, the biosensor demonstrated an impressive detection threshold for pyocyanin, suggesting that it could effectively identify Pseudomonas aeruginosa in various sample matrices, including clinical samples or environmental swabs.

Moreover, the researchers conducted a comparative analysis against traditional detection methods, highlighting the advantages of their biosensor in terms of speed and cost. While standard methods can take hours or even days to yield results, the D. zeae WH1 biosensor produced significant readings within minutes. This dramatic reduction in diagnostic turnaround time is critical in clinical settings where rapid decision-making can prevent further complications, such as sepsis or pneumonia.

In addressing the broader implications of their findings, the authors emphasize that this biosensor could pave the way for the development of a portable diagnostic tool. Such a device could be particularly beneficial in resource-limited settings, where access to advanced laboratory facilities is often restricted. By creating an affordable diagnostic solution, the researchers hope to bridge the gap in early detection, ultimately leading to improved patient care and better health outcomes.

An interesting aspect of the study touches upon the environmental ramifications of using biosensors derived from natural organisms. By employing a bacterium that is part of the microbiome, the researchers are also advocating for a more sustainable approach to diagnostics. This method minimizes reliance on synthetic chemicals and potentially hazardous materials often associated with conventional testing procedures.

Furthermore, the versatility of Dickeya zeae WH1 extends beyond pyocyanin detection. Future studies may explore its application in sensing other microbial metabolites, thus broadening the scope of its utility in microbiological research and infection detection. This flexibility presents an exciting frontier in biosensor technology, where the integration of different microbial sensors could lead to multiplexed detection systems.

As the research community continues to explore the genetic and biochemical pathways associated with microbial interactions, the potential for novel biosensor development seems limitless. The advancements in the understanding of bacterial sensing mechanisms, as demonstrated by this study, open doors to innovative diagnostic tools that are not only efficient but also environmentally friendly.

Additionally, the team plans to collaborate with clinicians and microbiologists to further validate the biosensor’s effectiveness in real-world healthcare scenarios. This step is crucial for transitioning laboratory findings into practical applications that can impact patient management in hospitals and clinics.

The implications of this study resonate well beyond academic circles. The ability to rapidly and accurately track the presence of infectious agents like Pseudomonas aeruginosa could transform how healthcare providers approach infection control. As antibiotic resistance continues to pose a significant threat globally, early detection presents one of the most viable strategies for mitigating the impact of resistant strains.

In conclusion, the research conducted by Tan, Ju, and Feng serves as a pivotal step forward in the realm of microbial diagnostics. By utilizing Dickeya zeae WH1 as a biosensor for pyocyanin, they have not only showcased the potential of microbial systems in detection but have also highlighted the importance of accessibility and sustainability in medical technology. The future holds promise for the integration of these concepts into mainstream diagnostic practices, ensuring that healthcare can meet the challenges posed by evolving pathogens efficiently and effectively.

Subject of Research: Detection of pyocyanin produced by Pseudomonas aeruginosa using Dickeya zeae WH1 as a biosensor.

Article Title: Dickeya zeae WH1 as sensor for cost-effective detection of pyocyanin produced by Pseudomonas aeruginosa.

Article References:
Tan, X., Ju, G., Feng, D. et al. Dickeya zeae WH1 as sensor for cost-effective detection of pyocyanin produced by Pseudomonas aeruginosa. Int Microbiol (2025). https://doi.org/10.1007/s10123-025-00676-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10123-025-00676-1

Keywords: Biosensors, Pseudomonas aeruginosa, Pyocyanin detection, Dickeya zeae WH1, Microbial diagnostics, Infection control, Antimicrobial resistance.

The research highlights the alarming rise of Pseudomonas aeruginosa as a leading cause of nosocomial infections. The bacterium has acquired various mechanisms to evade conventional antibiotic therapies. This resistance not only complicates treatment options but also significantly increases morbidity and mortality rates. As such, the scientific community is in dire need of alternative therapeutic strategies that can effectively neutralize such resilient pathogens.

The application of nanotechnology in medicine has opened up exciting avenues for the development of targeted drug delivery systems. The recent study focuses on the encapsulation of allicin—a compound derived from garlic known for its antibacterial properties—within biocompatible alginate-casein nanocapsules. This innovative approach aims to enhance the bioavailability of allicin, allowing for more effective delivery to the site of infection. By employing this method, researchers hope to circumvent some of the limitations associated with traditional antibiotic formulations.

Allicin, the active component in garlic, has been shown to exhibit potent antibacterial effects. However, its application in clinical settings has been hindered by its instability and rapid degradation. By encapsulating allicin in alginate-casein nanocapsules, researchers aim to provide a protective environment that preserves allicin’s integrity while facilitating its controlled release. This controlled release mechanism could result in prolonged antibacterial activity, offering a strategic advantage in combating resistant strains like Pseudomonas aeruginosa.

In their experiments, Homaei and colleagues evaluated the antibacterial efficacy of these innovative nanocapsules in vitro. The results demonstrated a significant reduction in bacterial growth, indicating that the alginate-casein nanocapsules effectively delivered allicin to the targeted bacterial cells. The researchers observed that the encapsulation process not only enhanced the stability of allicin but also increased its potency against multidrug-resistant strains.

One of the key advantages of using alginate-casein nanocapsules is their biocompatibility. Both alginate and casein are natural polymers that are generally recognized as safe, making them suitable candidates for pharmaceutical applications. Their use in drug delivery systems is particularly promising because they minimize the risk of adverse reactions when administered to patients. This biocompatibility further underscores the potential of this approach in translational medicine.

Another noteworthy aspect of the study is its focus on the mechanisms of action of allicin against Pseudomonas aeruginosa. Research indicates that allicin may interfere with bacterial enzymatic processes and disrupt the integrity of bacterial membranes. By elucidating these mechanisms, the study not only provides insight into the therapeutic potential of allicin but also paves the way for the rational design of new antimicrobial agents.

Furthermore, the investigation into nanoparticle technology in the context of combating antibiotic resistance has broader implications for the field of microbiology. The successful application of such nanocapsules could inspire subsequent research exploring the encapsulation of other therapeutics, including additional natural compounds that possess antimicrobial properties. This could ultimately contribute to the development of a new class of drugs that effectively target resistant strains of various pathogens.

However, the journey from laboratory findings to clinical use is not without challenges. While the research demonstrates promising results, further studies are necessary to assess the safety and efficacy of these nanocapsules in vivo. The transition to clinical trials will require careful consideration of dosage, administration routes, and patient selection criteria to ensure optimal therapeutic outcomes.

It is crucial to remain cognizant of the evolving landscape of antibiotic resistance and the need for innovative solutions. As the research community continues to explore alternative strategies, the potential of using nanotechnology in medicine remains a focal point of interest. The intersection of natural compounds like allicin with advanced drug delivery systems could mark a significant milestone in the battle against resistant bacteria.

The findings of Homaei, Ghourchian, and Piri-Gharaghie stand as a beacon of hope in confronting the challenges posed by multidrug-resistant Pseudomonas aeruginosa. Their work serves as an important reminder of the untapped potential of natural antimicrobial agents when paired with novel delivery methods. The study underscores the importance of continued research and investment in exploring innovative approaches to infection management.

As we anticipate the results of ongoing and future studies, the role of interdisciplinary collaboration will be paramount. Pharmacologists, microbiologists, and clinical researchers must unite to advance the development and application of these promising nanotechnology-based solutions. By harnessing the power of science and innovation, we can aspire to a future where effective antimicrobial therapy is available to all patients, regardless of the resilience of their bacterial foes.

Moreover, the implications of this research extend beyond practical applications; they serve as a call to action for the scientific community at large. It is imperative to prioritize research funding for alternative antimicrobials, enhance our understanding of resistance mechanisms, and foster an environment conducive to innovation. The health of our global population may very well depend on our ability to adapt and evolve our strategies in the face of ever-growing threats posed by microbial resistance.

In conclusion, the work of Homaei and colleagues offers a glimpse into the future of antibacterial therapies. The creation of alginate-casein nanocapsules for the controlled delivery of allicin represents a promising advancement in combatting multidrug-resistant Pseudomonas aeruginosa. As research in this area progresses, it is essential to keep the momentum going, continually seeking new methods and technologies that can safeguard public health against the rising tide of antibiotic resistance.

Subject of Research: Antibacterial activity of alginate-casein nanocapsules containing allicin against multidrug-resistant Pseudomonas aeruginosa.

Article Title: Antibacterial activity of alginate-casein nanocapsules containing allicin against multidrug-resistant Pseudomonas aeruginosa.

Article References:
Homaei, S., Ghourchian, H. & Piri-Gharaghie, T. Antibacterial activity of alginate-casein nanocapsules containing allicin against multidrug-resistant Pseudomonas aeruginosa.
Int Microbiol (2025). https://doi.org/10.1007/s10123-025-00697-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10123-025-00697-w

Keywords: antimicrobial resistance, allicin, Pseudomonas aeruginosa, nanotechnology, drug delivery systems, biocompatibility.

Invasive mold infections, often occurring in individuals undergoing cancer treatments or immunosuppressive therapies, represent a dire clinical challenge owing to their aggressive nature and high mortality rates, sometimes reaching 85 percent. Traditional diagnostic modalities struggle with the timely and precise identification of these infections predominantly because the clinical presentation overlaps with other inflammatory conditions, and existing biomarkers lack comprehensive sensitivity. The emergence of ^18F-FDS PET imaging addresses this critical gap by targeting metabolic pathways unique to fungal pathogens.

The team, led by Dr. Carlos Ruiz-Gonzalez, employed rigorous in vitro assays to evaluate ^18F-FDS uptake across 30 diverse mold strains isolated from infected patients. These models confirmed the tracer’s rapid and specific assimilation by living fungi, including strains resistant to conventional antifungal drugs, while demonstrating no uptake in heat-killed molds or human cellular tissues. This specificity underscores the tracer’s potential as an unequivocal indicator of active mold infection rather than mere inflammation or colonization.

Preclinical investigations in murine models with immunodeficiencies further substantiated these findings. Using PET/CT imaging, ^18F-FDS accurately delineated fungal lesions within critical anatomical sites such as the lungs, brain, and sinuses. Notably, it differentiated these infections from sterile inflammatory processes, a feat that is often elusive with current imaging technologies. The precision in distinguishing infectious from non-infectious pathology could thwart unnecessary invasive procedures and facilitate targeted antifungal therapy.

Clinical translation of this imaging approach involved four human patients with confirmed invasive mold infections and five control subjects burdened with inflammatory diseases or malignancies absent of infection. Consistently, ^18F-FDS PET scans revealed the precise localization of fungal infiltrates, including cerebral infections, with remarkable clarity. Intriguingly, the tracer identified a cerebral mold infection that was previously undetected by magnetic resonance imaging (MRI), highlighting its superior sensitivity and the critical role nuclear molecular imaging can play in complex cases.

The biochemical underpinnings of ^18F-FDS PET imaging rest on its derivation from ^18F-Fluorodeoxyglucose (^18F-FDG), a well-established radiotracer in oncological diagnostics. However, ^18F-FDS exploits unique microbial metabolic pathways by mimicking sorbitol, a sugar alcohol preferentially processed by many fungi. This metabolic specificity confers the radiotracer’s high affinity for living molds while sparing human cells, thereby providing a molecular signature exclusive to fungal infection sites. Moreover, the facile synthesis of ^18F-FDS from ^18F-FDG ensures scalability and accessibility in clinical settings worldwide.

The implications of this technology extend beyond diagnostic precision; it could redefine therapeutic monitoring. Current antifungal treatments demand protracted courses often complicated by toxicity and variable patient response. ^18F-FDS PET imaging facilitates dynamic monitoring of fungal burden, enabling clinicians to assess treatment efficacy in near real-time and adapt therapeutic regimens accordingly. This capability can significantly reduce morbidity and healthcare costs associated with invasive fungal diseases.

Furthermore, the tracer’s utility in detecting a wide array of mold species, including emerging drug-resistant variants, positions it as an indispensable tool in combating the rising tide of fungal antimicrobial resistance. As invasive mold infections become increasingly prevalent amid expanding populations of immunocompromised individuals, the integration of ^18F-FDS PET into clinical practice could profoundly impact global health outcomes.

While these preliminary results are promising, further studies are essential to validate ^18F-FDS’s performance across diverse patient populations and mold species, and to optimize imaging protocols. Researchers envision expanded trials to refine quantification metrics, explore potential false positives in complex inflammatory conditions, and integrate this modality into standard care pathways. The convergence of nuclear medicine and infectious disease diagnostics heralded by this innovation represents a paradigm shift in how clinicians approach invasive fungal infections.

Dr. Ruiz-Gonzalez emphasizes the transformative potential of this approach: “^18F-FDS PET imaging tasks molecular specificity with diagnostic speed, offering a long-awaited solution to an elusive clinical problem. By enabling noninvasive, precise detection of invasive molds, we can guide timely interventions that save lives and preserve organ function.” Given its ready synthesis and adaptability, ^18F-FDS is poised to become a globally deployable diagnostic asset, particularly valuable in resource-limited settings where invasive procedures and sophisticated biomarker assays are less accessible.

The Society of Nuclear Medicine and Molecular Imaging continues to champion such innovations that blend cutting-edge molecular imaging techniques with urgent clinical needs. As this tracer progresses through clinical validation stages, the anticipation is that ^18F-FDS PET will redefine infectious disease diagnostics, fostering earlier interventions, personalized treatment plans, and improved survival rates for vulnerable patient populations worldwide. Harnessing the power of molecular imaging to confront fungal pathogens may well herald a new era in the management of invasive mold infections.

Subject of Research: Noninvasive detection of invasive mold infections using PET radiotracer ^18F-Fluorodeoxysorbitol.

Article Title: 18F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections in patients.

News Publication Date: June 23, 2025.

Web References:
Link to Abstract
All 2025 SNMMI Annual Meeting Abstracts
Society of Nuclear Medicine and Molecular Imaging

References:
Ruiz-Gonzalez, C., Nino-Meza, O., Singh, M., Masias-Leon, Y., Kronenberg, A., Shamble, M., Chen, X., Sarhan, M., Tucker, E., Carroll, L., Cooke, K., Kates, O., Shoham, S., Zhang, S., & Jain, S. (2025). ^18F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections in patients. Journal of Nuclear Medicine, 66(supplement_1), 252079.

Image Credits: Images created by Ruiz-Gonzalez et al., Johns Hopkins University School of Medicine, Baltimore, MD.

Keywords: Molecular imaging, Medical imaging, Positron emission tomography, Invasive mold infections, ^18F-Fluorodeoxysorbitol, PET/CT, Fungal diagnostics, Immunocompromised patients, Radiotracers, Infectious disease imaging.